Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowe...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2006-01, Vol.21 (1), p.115-116 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 116 |
|---|---|
| container_issue | 1 |
| container_start_page | 115 |
| container_title | Movement disorders |
| container_volume | 21 |
| creator | Sullivan, Kelly L. Staffetti, Joseph F. Hauser, Robert A. Dunne, Peter B. Zesiewicz, Theresa A. |
| description | We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society |
| doi_str_mv | 10.1002/mds.20666 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70689011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70689011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5236-b37faea4921e7f9dc5c64a238153eb70086dbc40ace6d46b4ede234c0fa9428e3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EotuWA18A-QKlh7T-7-SIWtgiLRSJAhIXy3EmYEjsrScr6LcnZRd6Qpzm8nvvzbwh5DFnJ5wxcTp2eCKYMeYeWXAteVULbe-TBatrXUle6z2yj_iNMc41Nw_JHjdcCWvNgqyu4ItHKLmjzz_DkHIZj2mfC52-Ap0K-GmENNHc05ATTnHtp5gTjYm-8-V7TJjTEdIuIswuh-RB7weER7t5QD68enl1dlGtLpevz16sqqCFNFUrbe_Bq0ZwsH3TBR2M8kLW8-7QWsZq07VBMR_AdMq0CjoQUgXW-0aJGuQBebb1XZd8vQGc3BgxwDD4BHmDzjJTN_Ox_wUF51YyxWbweAuGkhEL9G5d4ujLjePM3Xbs5o7d745n9snOdNOO0N2Ru1Jn4OkO8Bj80BefQsQ7zqpGS3MberrlfsQBbv6d6N6cv_8TXW0VESf4-Vcxf8IZK612n94uXdNcfFyaRjstfwFuHqFX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21173040</pqid></control><display><type>article</type><title>Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sullivan, Kelly L. ; Staffetti, Joseph F. ; Hauser, Robert A. ; Dunne, Peter B. ; Zesiewicz, Theresa A.</creator><creatorcontrib>Sullivan, Kelly L. ; Staffetti, Joseph F. ; Hauser, Robert A. ; Dunne, Peter B. ; Zesiewicz, Theresa A.</creatorcontrib><description>We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.20666</identifier><identifier>PMID: 16142776</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; Biological and medical sciences ; constipation ; Constipation - drug therapy ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Double-Blind Method ; Female ; Gastrointestinal Agents - administration & dosage ; Gastrointestinal Motility - drug effects ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Humans ; Indoles - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Nervous system (semeiology, syndromes) ; Neurology ; Parkinson Disease - drug therapy ; Parkinson's disease ; Patient Satisfaction ; Serotonin 5-HT4 Receptor Agonists ; Serotonin Receptor Agonists - administration & dosage ; tegaserod ; Zelnorm</subject><ispartof>Movement disorders, 2006-01, Vol.21 (1), p.115-116</ispartof><rights>Copyright © 2005 Movement Disorder Society</rights><rights>2006 INIST-CNRS</rights><rights>Copyright (c) 2005 Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5236-b37faea4921e7f9dc5c64a238153eb70086dbc40ace6d46b4ede234c0fa9428e3</citedby><cites>FETCH-LOGICAL-c5236-b37faea4921e7f9dc5c64a238153eb70086dbc40ace6d46b4ede234c0fa9428e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.20666$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.20666$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17495360$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16142776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sullivan, Kelly L.</creatorcontrib><creatorcontrib>Staffetti, Joseph F.</creatorcontrib><creatorcontrib>Hauser, Robert A.</creatorcontrib><creatorcontrib>Dunne, Peter B.</creatorcontrib><creatorcontrib>Zesiewicz, Theresa A.</creatorcontrib><title>Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease</title><title>Movement disorders</title><addtitle>Mov. Disord</addtitle><description>We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>constipation</subject><subject>Constipation - drug therapy</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gastrointestinal Agents - administration & dosage</subject><subject>Gastrointestinal Motility - drug effects</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Humans</subject><subject>Indoles - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Patient Satisfaction</subject><subject>Serotonin 5-HT4 Receptor Agonists</subject><subject>Serotonin Receptor Agonists - administration & dosage</subject><subject>tegaserod</subject><subject>Zelnorm</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxS0EotuWA18A-QKlh7T-7-SIWtgiLRSJAhIXy3EmYEjsrScr6LcnZRd6Qpzm8nvvzbwh5DFnJ5wxcTp2eCKYMeYeWXAteVULbe-TBatrXUle6z2yj_iNMc41Nw_JHjdcCWvNgqyu4ItHKLmjzz_DkHIZj2mfC52-Ap0K-GmENNHc05ATTnHtp5gTjYm-8-V7TJjTEdIuIswuh-RB7weER7t5QD68enl1dlGtLpevz16sqqCFNFUrbe_Bq0ZwsH3TBR2M8kLW8-7QWsZq07VBMR_AdMq0CjoQUgXW-0aJGuQBebb1XZd8vQGc3BgxwDD4BHmDzjJTN_Ox_wUF51YyxWbweAuGkhEL9G5d4ujLjePM3Xbs5o7d745n9snOdNOO0N2Ru1Jn4OkO8Bj80BefQsQ7zqpGS3MberrlfsQBbv6d6N6cv_8TXW0VESf4-Vcxf8IZK612n94uXdNcfFyaRjstfwFuHqFX</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Sullivan, Kelly L.</creator><creator>Staffetti, Joseph F.</creator><creator>Hauser, Robert A.</creator><creator>Dunne, Peter B.</creator><creator>Zesiewicz, Theresa A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>200601</creationdate><title>Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease</title><author>Sullivan, Kelly L. ; Staffetti, Joseph F. ; Hauser, Robert A. ; Dunne, Peter B. ; Zesiewicz, Theresa A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5236-b37faea4921e7f9dc5c64a238153eb70086dbc40ace6d46b4ede234c0fa9428e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>constipation</topic><topic>Constipation - drug therapy</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gastrointestinal Agents - administration & dosage</topic><topic>Gastrointestinal Motility - drug effects</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Humans</topic><topic>Indoles - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Patient Satisfaction</topic><topic>Serotonin 5-HT4 Receptor Agonists</topic><topic>Serotonin Receptor Agonists - administration & dosage</topic><topic>tegaserod</topic><topic>Zelnorm</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sullivan, Kelly L.</creatorcontrib><creatorcontrib>Staffetti, Joseph F.</creatorcontrib><creatorcontrib>Hauser, Robert A.</creatorcontrib><creatorcontrib>Dunne, Peter B.</creatorcontrib><creatorcontrib>Zesiewicz, Theresa A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sullivan, Kelly L.</au><au>Staffetti, Joseph F.</au><au>Hauser, Robert A.</au><au>Dunne, Peter B.</au><au>Zesiewicz, Theresa A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov. Disord</addtitle><date>2006-01</date><risdate>2006</risdate><volume>21</volume><issue>1</issue><spage>115</spage><epage>116</epage><pages>115-116</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16142776</pmid><doi>10.1002/mds.20666</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2006-01, Vol.21 (1), p.115-116 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70689011 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Biological and medical sciences constipation Constipation - drug therapy Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Double-Blind Method Female Gastrointestinal Agents - administration & dosage Gastrointestinal Motility - drug effects Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Indoles - administration & dosage Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Parkinson Disease - drug therapy Parkinson's disease Patient Satisfaction Serotonin 5-HT4 Receptor Agonists Serotonin Receptor Agonists - administration & dosage tegaserod Zelnorm |
| title | Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A45%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tegaserod%20(Zelnorm)%20for%20the%20treatment%20of%20constipation%20in%20Parkinson's%20disease&rft.jtitle=Movement%20disorders&rft.au=Sullivan,%20Kelly%20L.&rft.date=2006-01&rft.volume=21&rft.issue=1&rft.spage=115&rft.epage=116&rft.pages=115-116&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.20666&rft_dat=%3Cproquest_cross%3E70689011%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21173040&rft_id=info:pmid/16142776&rfr_iscdi=true |